Why does omeprazole's acid-suppressing effect last far longer than its roughly 30-60 minute plasma half-life would suggest?

It binds the parietal cell H+/K+-ATPase essentially irreversibly, so suppression lasts until new pump molecules are made — The drug is cleared from plasma quickly, but because it permanently disables the proton pumps it reaches, acid suppression persists for about 72 hours regardless of how fast the parent drug itself is eliminated.

It is stored in adipose tissue and released slowly

Its active metabolite has a 72-hour half-life

It saturates plasma proteins, delaying renal clearance

What must happen before a PPI becomes pharmacologically active?

Acid-catalysed conversion within the acidic secretory canaliculus of the parietal cell — PPIs are prodrugs that require the very acidic environment of the parietal cell's secretory canaliculus to convert into their active, pump-binding form — which is also why timing the dose before a meal (when pumps are about to activate) matters for effect.

Renal excretion of an inactive conjugate

First-pass hepatic glucuronidation

A patient on clopidogrel after a coronary stent is started on a PPI for reflux. Which choice best reflects the current evidence?

Omeprazole and esomeprazole are the PPIs specifically documented to meaningfully reduce clopidogrel's antiplatelet effect via CYP2C19; other PPIs such as pantoprazole have been identified as an alternative — The interaction is drug-specific, not class-wide. Omeprazole reduced clopidogrel's antithrombotic effect by roughly half in the evidence that prompted the original warning, and the subsequent clarification specifically named omeprazole (and by extension esomeprazole) rather than the whole class, pointing to pantoprazole as an alternative.

All PPIs are equally contraindicated with clopidogrel

PPIs have no interaction with clopidogrel at any dose

The interaction only matters if clopidogrel is taken more than 12 hours after the PPI

Which of these is the most accurate statement about long-term PPI use and bone fracture risk?

Multiple epidemiological studies associate high-dose, long-term (roughly one year or more) PPI use with hip, wrist and spine fracture, through a plausible but not fully settled mechanism — The signal is real enough that regulators added labeling language about it, but the mechanistic and epidemiological picture is explicitly described in the review literature as inconsistent rather than settled, and the risk is tied to higher doses and longer duration rather than any exposure.

There is no plausible mechanism and no epidemiological association

The FDA has proven PPIs directly cause osteoporosis

The risk is identical regardless of dose or duration of use

What is the mechanistic difference between PPIs and H2-receptor antagonists that a student should never flatten into "PPIs are just stronger"?

PPIs irreversibly inhibit the H+/K+-ATPase itself; H2RAs reversibly and competitively block histamine H2 receptors upstream of the pump — PPIs target the final common step of acid secretion irreversibly; H2RAs block one of several inputs to that pump, reversibly and competitively. That difference in target and reversibility, not simply relative strength, explains their different onset, depth and duration of acid suppression.

PPIs act on histamine receptors while H2RAs act on the proton pump directly

There is no mechanistic difference, only a difference in tablet size

H2RAs are prodrugs requiring acid activation, while PPIs are not

Why can hypomagnesemia from long-term PPI use fail to respond to magnesium supplementation alone?

The mechanism is thought to involve reduced intestinal magnesium absorption tied to the drug itself, so correction generally requires stopping the PPI — Because the deficiency is tied to the PPI's effect on intestinal magnesium absorption rather than simple dietary insufficiency, supplementation without addressing the underlying cause often fails, and correction typically depends on stopping the drug — a decision for the treating clinician.

PPIs increase renal magnesium excretion, which supplementation cannot outpace

Magnesium supplements are inactivated by gastric acid in PPI users

It is a laboratory artefact, not a true deficiency

Pharmacology · Acid-suppressing agents

Proton pump inhibitors

Prodrugs that bind irreversibly to the parietal cell H+/K+-ATPase, the final common step of gastric acid secretion, giving the most complete and durable acid suppression of any oral drug class but at the cost of long-term risks that only appear with sustained use.

Quick revision

PPIs are prodrugs activated by stomach acid that irreversibly bind the parietal cell H+/K+-ATPase, giving the deepest acid suppression available — full effect takes a few days to build and a few days to wear off after stopping, which is why timing and long-term risk both look different from H2-receptor antagonists.

Mechanism: inhibit the parietal cell H+/K+-ATPase pump, the final step of gastric acid secretion, after acid-catalysed activation in the secretory canaliculus. (1) (3)
The FDA-approved class includes omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole and rabeprazole. (1)
Binding is essentially irreversible for the life of that pump molecule, so the effect outlasts the drug's own short plasma half-life (about 30-60 minutes for omeprazole) by many hours. (2)
Full acid-suppressing effect takes a few days to build, unlike H2-receptor antagonists, which act faster but suppress acid less completely. (1)
Most common adverse effects in the omeprazole label are headache (6.9%), abdominal pain (5.2%), nausea (4.0%), diarrhea (3.7%), vomiting (3.2%) and flatulence (2.7%). (3)
Long-term use is linked to hypomagnesemia, reduced vitamin B12 and iron absorption, Clostridioides difficile and other enteric infection risk, and a fracture signal that the evidence base still calls inconsistent. (1) (2)
Omeprazole and esomeprazole specifically reduce clopidogrel's antiplatelet effect through shared CYP2C19 metabolism — this is not a whole-class effect, since not every PPI inhibits CYP2C19 to the same degree. (4)
Stopping a PPI after prolonged use can cause rebound acid hypersecretion, with acid output temporarily higher than before treatment started. (1)

Overview

Proton pump inhibitors are the most potent acid-suppressing drug class in routine use, and omeprazole is regularly cited among the most prescribed medicines in the United States. The FDA-approved members are omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole and rabeprazole, used for duodenal and gastric ulcer, gastro-oesophageal reflux disease, erosive oesophagitis maintenance, NSAID-induced ulcer prevention, Zollinger-Ellison syndrome and as part of Helicobacter pylori eradication regimens. (1) (3)

Each drug in the class is an inactive prodrug until it reaches the acidic secretory canaliculus of the gastric parietal cell, where acid catalyses its conversion to the active sulphenamide form. That active form binds the H+/K+-ATPase — the pump that carries out the final step of acid secretion — essentially irreversibly, so a single dose can suppress acid output for around 72 hours even though the parent drug itself is cleared from plasma within an hour or two. (1) (2)

That same irreversible, prodrug-dependent mechanism is what separates PPIs from the faster but shallower H2-receptor antagonists, and it is also the reason this class carries risks that only surface with sustained use rather than with a single course: hypomagnesemia, reduced vitamin B12 and iron absorption, an association with Clostridioides difficile and other enteric infection, a fracture signal in long-term high-dose users, and rebound acid hypersecretion on withdrawal. None of these are reasons to self-adjust therapy — they are reasons long-term use should stay under a clinician's review. (1)

Classification and drug examples

All PPIs share the same target and the same irreversible mechanism; what differs between them is formulation, isomer chemistry and — critically for one member — the degree to which they inhibit CYP2C19 and therefore interact with clopidogrel.

Omeprazole and its enantiomer/related agents

Omeprazole is the class prototype; esomeprazole is its S-isomer, marketed separately. Both are the members specifically documented to meaningfully inhibit CYP2C19 and reduce clopidogrel's antiplatelet effect. (4)

Omeprazole (Prilosec) · Oral — Class prototype; one of the most prescribed drugs in the United States. (1)
Esomeprazole (Nexium) · Oral/IV — The S-isomer of omeprazole; shares its CYP2C19 clopidogrel interaction. (4)

Other FDA-approved PPIs

Same H+/K+-ATPase mechanism; regulators have pointed to this group, particularly pantoprazole, as an alternative when a PPI is needed alongside clopidogrel because CYP2C19 inhibition is less pronounced. (1) (4)

Lansoprazole (Prevacid) · Oral — FDA-approved PPI available in both prescription and over-the-counter strengths. (1)
Dexlansoprazole (Dexilant) · Oral — The R-enantiomer of lansoprazole, formulated for a dual-release profile. (1)
Pantoprazole (Protonix) · Oral/IV — Identified as an alternative PPI when clopidogrel co-therapy is needed, because it inhibits CYP2C19 less than omeprazole/esomeprazole. (4)
Rabeprazole (Aciphex) · Oral — FDA-approved PPI sharing the class mechanism and indications. (1)

Mechanism of action

PPIs are inactive prodrugs that are protonated and converted to their active sulphenamide form only inside the acidic secretory canaliculus of the gastric parietal cell, where they bind the H+/K+-ATPase covalently and essentially irreversibly, shutting down the final common step of gastric acid secretion.

Molecular target: H+/K+-ATPase (the gastric proton pump) on the secretory surface of the parietal cell
Pharmacodynamic effect: not applicable (not an antimicrobial class)
Effect kinetics: not applicable (not an antimicrobial class)

The prodrug is absorbed and reaches the parietal cell
The inactive drug is absorbed and travels via the bloodstream to the gastric parietal cell, where it concentrates in the acidic secretory canaliculus. (1)
Acid activates the drug
The very low pH of the secretory canaliculus catalyses conversion of the prodrug into its active sulphenamide form — this acid-dependent activation step is why the drug must be present when the pumps are becoming active, typically before a meal. (1)
The active form binds the H+/K+-ATPase covalently
The active sulphenamide forms a covalent bond with cysteine residues on the H+/K+-ATPase, the pump responsible for the final step of hydrogen ion secretion into the gastric lumen. (1) (3)
The bound pump is disabled essentially irreversibly
Because the bond is covalent, that individual pump molecule stays inactive for the rest of its lifespan; acid secretion only resumes as the parietal cell synthesises new, unbound pumps. (2)
Suppression outlasts the drug's own presence in plasma
Because the effect depends on how many pumps have been permanently disabled rather than on ongoing drug concentration, acid suppression persists for roughly 72 hours even though the parent drug's own plasma half-life is around 30-60 minutes. (2) (1)

Major clinical uses

Read each row as drug → indication → role in therapy. Treatment is always directed by the treating clinician.

Drug	Indication	Role	Note
Omeprazole	Short-term treatment of active duodenal and gastric ulcer, treatment of gastro-oesophageal reflux disease, maintenance of healing of erosive oesophagitis, and treatment of pathological hypersecretory conditions such as Zollinger-Ellison syndrome	first-line	One of the FDA-labelled indications for the class prototype; specific dosing and duration are set by the treating clinician. (3)
PPIs as a class	Component of standard triple therapy for H. pylori eradication, alongside antibiotics	first-line component	The PPI itself does not treat the infection but raises gastric pH to support the antibiotics and mucosal healing. (1)
PPIs as a class	Prevention of NSAID-induced peptic ulcer in patients who need ongoing NSAID therapy	prophylactic	Used specifically because sustained, deep acid suppression protects the gastroduodenal mucosa during long-term NSAID exposure. (1)
PPIs as a class	Non-erosive reflux disease and oesophagitis	first-line	The class's deep, sustained acid suppression is the reason it outperforms H2-receptor antagonists for healing erosive disease. (1)
Pantoprazole	Preferred PPI choice when acid suppression is needed alongside ongoing clopidogrel therapy	targeted	Chosen specifically for its comparatively lower CYP2C19 inhibition relative to omeprazole and esomeprazole. (4)

Pharmacokinetics

Drug	Route	Absorption	Metabolism	Elimination	Half-life	Adjust in
Omeprazole	Oral	Acid-labile prodrug, formulated as delayed-release to survive the stomach before absorption in the small intestine	Extensive hepatic metabolism via CYP2C19 (major) and CYP3A4 (minor)	Hepatic metabolites, primarily renal excretion	Approximately 30-60 minutes in healthy adults; longer with hepatic impairment	Hepatic impairment reduces clearance; see prescribing reference (2)

Plasma half-life across the class is short, but pharmacological effect is not — because binding to the proton pump is essentially irreversible, acid suppression lasts far longer than the drug's own presence in the blood, and full effect can take a few days of dosing to build. (2) (1)
Because activation depends on gastric acid, PPIs are conventionally taken before a meal, when the proton pumps are about to become active. (1)
This page gives no dose regimens by design. Doses depend on indication, formulation, hepatic function and the treating clinician's assessment, and belong in a current prescribing reference.

Adverse effects

Common

Headache: Reported in 6.9% of omeprazole users in FDA labelling, the most frequent adverse reaction in the class. (3)
Abdominal pain, nausea, diarrhoea, vomiting and flatulence: Reported at rates of roughly 2.7% to 5.2% for omeprazole in FDA labelling; these are the other adverse reactions occurring in more than 2% of users. (3)

Serious adverse effects

Hypomagnesemia: Can develop with prolonged use and may not respond to magnesium supplementation alone; severe cases have been associated with tetany, seizures and cardiac arrhythmia. Any symptoms suggestive of low magnesium — muscle cramps, irregular heartbeat, seizures — need prompt medical assessment. (1)
Clostridioides difficile and other enteric infection risk: Reduced gastric acidity is associated with increased risk of C. difficile-associated diarrhoea and other enteric infections. New or worsening diarrhoea during PPI therapy warrants medical review. (1) (2)
Fracture risk with long-term, high-dose use: Multiple epidemiological studies associate long-term (around one year or more), high-dose PPI use with hip, wrist and spine fracture; the review literature describes the underlying data as inconsistent rather than settled. Ongoing high-dose or long-duration PPI therapy is a decision to review periodically with a clinician rather than continue indefinitely without reassessment. (1)
Rebound acid hypersecretion on withdrawal: Discontinuation after prolonged use can produce acid output temporarily higher than before treatment began. Any change to long-term PPI therapy should be planned with the prescribing clinician rather than stopped abruptly on the patient's own initiative. (1)
Acute tubulointerstitial nephritis: A rare but recognised idiosyncratic reaction associated with PPI use. Unexplained kidney function changes during PPI therapy warrant medical evaluation. (2)

Drug-specific effects

PPIs as a class: Vitamin B12 and iron deficiency have been reported with prolonged use, though clinically significant B12 deficiency from this cause is described as rare. (1)

Contraindications, precautions and interactions

Contraindications

Known hypersensitivity to the specific PPI or its excipients. (2)
Co-administration with rilpivirine-containing antiretroviral regimens, for omeprazole specifically, because gastric acid suppression reduces rilpivirine absorption. (2)

Precautions

Severe hepatic impairment, given the class's dependence on hepatic CYP2C19/CYP3A4 metabolism. (1)
Symptomatic response to a PPI does not exclude gastric malignancy, so persistent or alarm symptoms need proper clinical evaluation rather than continued self-treatment. (3)

Drug interactions

Clopidogrel (specifically with omeprazole or esomeprazole): Shared CYP2C19 metabolism reduces clopidogrel's antiplatelet activation, cutting its antithrombotic effect substantially; pantoprazole has been identified as a lower-interaction alternative when a PPI is genuinely needed. (4)
Phenytoin, warfarin, diazepam: Clearance of these drugs can be delayed through hepatic enzyme effects, requiring monitoring. (1)
Ketoconazole and other pH-dependent-absorption drugs: Reduced gastric acidity can impair absorption of drugs that require an acidic environment to dissolve or absorb. (1)
Digoxin: Digoxin absorption can be enhanced by reduced gastric acidity, meriting extra caution and monitoring. (1)

Comparison tables

Which PPIs matter for clopidogrel co-therapy

The interaction is drug-specific within the class, not a flat class effect. A prescribing reference and the treating clinician govern actual co-therapy decisions.

PPI	CYP2C19 inhibition	Clopidogrel interaction
Omeprazole	Meaningful	Documented to reduce clopidogrel's antiplatelet effect substantially; avoid combining (4)
Esomeprazole	Meaningful	Same CYP2C19-mediated concern as omeprazole, its parent compound's S-isomer (4)
Pantoprazole	Comparatively lower	Identified by regulators as an alternative when a PPI is needed with clopidogrel (4)

High-yield exam pearls

PPIs need acid to work. (1) They are prodrugs that only become active after acid-catalysed conversion inside the parietal cell's acidic secretory canaliculus, which is why they are usually dosed before a meal, when the pumps are about to activate.
The drug's plasma half-life is not the story — the pump's lifespan is. (2) (1) Omeprazole's plasma half-life is roughly 30 minutes to an hour, but because binding to the H+/K+-ATPase is effectively irreversible, acid suppression persists for around 72 hours until new pump molecules are synthesised.
Not all PPIs interact with clopidogrel the same way. (4) Omeprazole and esomeprazole meaningfully inhibit CYP2C19, the enzyme that activates clopidogrel, and cut its antiplatelet effect roughly in half; other PPIs inhibit that enzyme far less, which is why regulators have pointed to pantoprazole as an alternative rather than banning the whole class alongside clopidogrel.
Stopping after long-term use is not automatically the safe default. (1) Prolonged acid suppression can be followed by rebound acid hypersecretion once the drug is withdrawn, so any change in a long-term PPI regimen is a decision for the treating clinician, not something to do unprompted.
The bone-fracture link is real in the data but not settled in the mechanism. (1) Multiple studies associate long-term, high-dose PPI use with hip, wrist and spine fracture, plausibly through calcium malabsorption and altered gastrin/B12 handling, but the class's own review literature is explicit that the data are not consistent enough to call this settled.
Hypomagnesemia from a PPI does not respond to magnesium supplements alone. (1) The mechanism is thought to involve reduced intestinal magnesium absorption tied to the drug itself, so correction generally requires stopping the PPI rather than simply replacing magnesium — a decision that belongs to the prescriber weighing the original indication.

Common exam traps

Trap: "PPIs and H2-receptor antagonists work the same way, just at different strengths." Actually: They act on different targets by different chemistry: PPIs irreversibly inhibit the H+/K+-ATPase itself (the final common pathway of acid secretion), while H2-receptor antagonists reversibly and competitively block histamine H2 receptors one step upstream. That mechanistic difference, not just potency, is why PPIs take longer to reach full effect and why H2RAs are the faster-acting but shallower option. (1)
Trap: "Every PPI interacts with clopidogrel, so none should ever be combined with it." Actually: The clinically significant CYP2C19 interaction is specifically documented for omeprazole and esomeprazole. Regulators have identified pantoprazole as an alternative precisely because PPIs do not inhibit CYP2C19 uniformly — treating this as a flat class effect overstates the evidence for some agents and understates it for others. (4)
Trap: "A short plasma half-life means the drug's effect wears off quickly." Actually: Omeprazole's plasma half-life is about 30-60 minutes, but its acid-suppressing effect lasts around 72 hours because the drug has already permanently disabled the pump molecules it bound. Half-life describes the drug in the blood, not the duration of the pharmacological effect for this class. (2) (1)
Trap: "Stopping a long-term PPI has no consequence beyond losing the acid suppression." Actually: Withdrawal after sustained use can trigger rebound acid hypersecretion, with gastric acid temporarily higher than the pre-treatment baseline — a real physiological effect, not just symptom recurrence. (1)

Self-test questions

Answers are hidden until you open them. These questions are written from this page's cited content and are for study only — they are not clinical guidance.

Why does omeprazole's acid-suppressing effect last far longer than its roughly 30-60 minute plasma half-life would suggest?
- It is stored in adipose tissue and released slowly
- It binds the parietal cell H+/K+-ATPase essentially irreversibly, so suppression lasts until new pump molecules are made
- Its active metabolite has a 72-hour half-life
- It saturates plasma proteins, delaying renal clearance
Show answer
Answer: It binds the parietal cell H+/K+-ATPase essentially irreversibly, so suppression lasts until new pump molecules are made
The drug is cleared from plasma quickly, but because it permanently disables the proton pumps it reaches, acid suppression persists for about 72 hours regardless of how fast the parent drug itself is eliminated. (2) (1)
What must happen before a PPI becomes pharmacologically active?
- Renal excretion of an inactive conjugate
- First-pass hepatic glucuronidation
- Acid-catalysed conversion within the acidic secretory canaliculus of the parietal cell
- Binding to plasma albumin
Show answer
Answer: Acid-catalysed conversion within the acidic secretory canaliculus of the parietal cell
PPIs are prodrugs that require the very acidic environment of the parietal cell's secretory canaliculus to convert into their active, pump-binding form — which is also why timing the dose before a meal (when pumps are about to activate) matters for effect. (1)
A patient on clopidogrel after a coronary stent is started on a PPI for reflux. Which choice best reflects the current evidence?
- All PPIs are equally contraindicated with clopidogrel
- Omeprazole and esomeprazole are the PPIs specifically documented to meaningfully reduce clopidogrel's antiplatelet effect via CYP2C19; other PPIs such as pantoprazole have been identified as an alternative
- PPIs have no interaction with clopidogrel at any dose
- The interaction only matters if clopidogrel is taken more than 12 hours after the PPI
Show answer
Answer: Omeprazole and esomeprazole are the PPIs specifically documented to meaningfully reduce clopidogrel's antiplatelet effect via CYP2C19; other PPIs such as pantoprazole have been identified as an alternative
The interaction is drug-specific, not class-wide. Omeprazole reduced clopidogrel's antithrombotic effect by roughly half in the evidence that prompted the original warning, and the subsequent clarification specifically named omeprazole (and by extension esomeprazole) rather than the whole class, pointing to pantoprazole as an alternative. (4)
Which of these is the most accurate statement about long-term PPI use and bone fracture risk?
- There is no plausible mechanism and no epidemiological association
- The FDA has proven PPIs directly cause osteoporosis
- Multiple epidemiological studies associate high-dose, long-term (roughly one year or more) PPI use with hip, wrist and spine fracture, through a plausible but not fully settled mechanism
- The risk is identical regardless of dose or duration of use
Show answer
Answer: Multiple epidemiological studies associate high-dose, long-term (roughly one year or more) PPI use with hip, wrist and spine fracture, through a plausible but not fully settled mechanism
The signal is real enough that regulators added labeling language about it, but the mechanistic and epidemiological picture is explicitly described in the review literature as inconsistent rather than settled, and the risk is tied to higher doses and longer duration rather than any exposure. (1)
What is the mechanistic difference between PPIs and H2-receptor antagonists that a student should never flatten into "PPIs are just stronger"?
- PPIs act on histamine receptors while H2RAs act on the proton pump directly
- PPIs irreversibly inhibit the H+/K+-ATPase itself; H2RAs reversibly and competitively block histamine H2 receptors upstream of the pump
- There is no mechanistic difference, only a difference in tablet size
- H2RAs are prodrugs requiring acid activation, while PPIs are not
Show answer
Answer: PPIs irreversibly inhibit the H+/K+-ATPase itself; H2RAs reversibly and competitively block histamine H2 receptors upstream of the pump
PPIs target the final common step of acid secretion irreversibly; H2RAs block one of several inputs to that pump, reversibly and competitively. That difference in target and reversibility, not simply relative strength, explains their different onset, depth and duration of acid suppression. (1)
Why can hypomagnesemia from long-term PPI use fail to respond to magnesium supplementation alone?
- The mechanism is thought to involve reduced intestinal magnesium absorption tied to the drug itself, so correction generally requires stopping the PPI
- PPIs increase renal magnesium excretion, which supplementation cannot outpace
- Magnesium supplements are inactivated by gastric acid in PPI users
- It is a laboratory artefact, not a true deficiency
Show answer
Answer: The mechanism is thought to involve reduced intestinal magnesium absorption tied to the drug itself, so correction generally requires stopping the PPI
Because the deficiency is tied to the PPI's effect on intestinal magnesium absorption rather than simple dietary insufficiency, supplementation without addressing the underlying cause often fails, and correction typically depends on stopping the drug — a decision for the treating clinician. (1)

Frequently asked questions

Are proton pump inhibitors and H2-receptor antagonists the same kind of drug?

No. PPIs irreversibly block the H+/K+-ATPase itself, the final step of acid secretion, while H2-receptor antagonists reversibly block histamine H2 receptors one step upstream. PPIs act more slowly to reach full effect but suppress acid more deeply and for longer. (1)

Why do PPIs need to be taken before a meal?

They are prodrugs that only become active in the presence of stomach acid, inside the parietal cell's secretory canaliculus. Dosing before a meal times the drug to be available when the pumps are becoming active. (1)

Do all PPIs interact with clopidogrel?

No. The clinically significant interaction, via CYP2C19 inhibition, is specifically documented for omeprazole and esomeprazole. Pantoprazole has been identified as an alternative with less effect on that enzyme. (4)

Is it safe to stop a long-term PPI on your own?

Stopping abruptly after prolonged use can cause rebound acid hypersecretion, and the original indication also needs reassessment. Any change to long-term PPI therapy should be discussed with the prescribing clinician. (1)

Do PPIs definitely cause fractures?

There is a real epidemiological association between long-term, high-dose PPI use and hip, wrist and spine fracture, but the review literature is explicit that the data are not fully consistent, and the mechanism is still debated. (1)

References

Proton Pump Inhibitors (StatPearls) StatPearls Publishing / NCBI Bookshelf, 2023
Omeprazole (StatPearls) StatPearls Publishing / NCBI Bookshelf, 2023
Omeprazole Delayed-Release Capsules, FDA prescribing information (DailyMed) U.S. National Library of Medicine / FDA, 2024
Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication PubMed Central, National Library of Medicine, 2016